Background: Evodiamine, a compound isolated from the Evodia rutaecarpa Bentham (Rutaceae), is known to have a potential anti-proliferative activity in human cancer cells. However, the growth inhibitory activity against lung cancer cells and the underlying molecular mechanisms have been poorly determined. The present study was designed to examine the anti-proliferative effect of evodiamine in A549 human lung cancer cells.
INTRODUCTION
Lung cancer is one of the most widely diagnosed cancer types in the world and leading cause of cancer-related death. 1 Despite major advances in development of various targeted therapeutic approaches, mortality related to lung cancer still remains at a high level. For lung cancer therapy, along with surgery, radiotherapy and immunotherapy, chemotherapy is one of the most common treatments.
During the past decade, platinum-based combinations with cytotoxic agents such as vinorelbine, gemcitabine and taxanes were used in lung cancer therapy. In recent years, gefitinib and erlotinib have been used clinically for treatment of lung cancer as targeted therapy. However, several side effects and drug resistance are also frequent problems in the course of therapy. 2 Thus, the development of new effective therapeutic agents to approach lung cancer is extremely necessary.
Evodiamine is a quinazolinecarboline alkaloid isolated from the fruit of Evodia rutaecarpa Bentham. 3 Evodiamine has been reported to have pharmacological activities of anti-inflammatory, anti-cardiovascular disease, anti-Alzheimer's disease, anti-microbial and anti-obesity. 4 In addition, evodiamine has anti-cancer effects and inhibits the growth of several types of human cancer cells in vitro and in vivo. [5] [6] [7] [8] In several reports, G2/M phase arrest is believed to be one of the major mechanisms of action for evodiamine against human cancer cells. 7, [9] [10] [11] However, the mechanisms of evodiamine in the growth-inhibitory activity against human lung cancer cells are poorly defined.
In this study, we examined the anti-proliferative effects of evodiamine in A549 human lung cancer cells. The mechanisms of action of cell cycle arrest and apoptosis were also investigated.
MATERIALS AND METHODS Approximately 20,000 cells were used for each analysis, and the distribution of cells in each phase of the cell cycle was displayed as histograms.
Western blot analysis
A549 human lung cancer cells were exposed with various concentrations of evodiamine for 24 h. After incubation, cells were lysed and protein concentrations were determined by BCA method. Each protein (40 μg) was subjec- using LAS-3000 Imager (Fuji Film Corp., Japan).
Statistical analysis
All of the experiments were repeated at least three times.
Data were expressed as the mean±standard deviation (SD)
for the indicated number of independently performed experiments and analyzed using Student's t-test. Values of P＜0.05 were considered statistically significant. the cell proliferation of each tested group was determined by the SRB staining method. As shown in Table 1 , among the test compounds, evodiamine exhibited the most potent anti-proliferative effects. Evodiamine exhibited a remarkable anti-proliferative activity with the IC50 value of 1.3 μM (Fig. 2) . The IC50 value of ellipticine, a positive control, was 0.8 μM in the A549 cells under the same experimental condition.
Effects of evodiamine on cell cycle distribution
To investigate the anti-proliferative mechanisms of evodiamine, A549 cells were treated with the indicated concentration of evodiamine for 24 h, and flow cytometric analysis was performed with propidium iodide (PI) staining. As shown in Fig. 3 , the distribution (%) of cells in the G2/M phase was markedly increased by evodiamine in a concentration-dependent manner. In addition, the treatment of evodiamine slightly increased the cell cycle distribution in the sub-G1 phase, indicative of apoptotic cell death.
Effects of evodiamine on the expression of G2/M phase cell cycle checkpoint proteins
To further elucidate whether cell cycle arrest is associated with the regulation of cell cycle checkpoint proteins, the expression of G2/M cell cycle regulatory proteins was examined by Western blot analysis. As shown in Fig. 4 , the expression of cyclin A, cyclin B1, cdk2 and p-cdc2 (Tyr15) was significantly decreased and the levels of p-chk1 (Ser345), p-chk2 (Thr68) and p-H2A.X (Ser139) were increased. Evodiamine treatment did not affect the levels of cdc2.
Effects of evodiamine on the apoptosis-and autophagy-related proteins
The changes in the expression of apoptosis-inducing signaling molecules were evaluated in evodiamine-treated A549 cells. Upon treatment with evodiamine for 24 h, the level of Bax was increased while Bcl-2 and procaspase-3 levels were decreased in A549 cells. However, the cleaved form of caspase-8 did not appeared (Fig. 5A ). In addition, the levels of LC3B-II and Beclin-1, autophagy markers were elevated by evodiamine treatment (Fig. 5B) .
Furthermore, evodiamine decreased the expression of p-ERK and ERK (Fig. 5C ). phase compared with control cells. This result is consistent with previous reported data on G2/M phase arrest by evodiamine. 7, 10, 11, 13 Cyclin B1 is a key component of the G2
DISCUSSION
to M phase transition. 14 In addition, cyclinA/Cdk2 complexes play a role in the initiation of mitosis in human cancer cells. 15 In this study, we found that the induction of cell cycle arrest at G2/M phase by evodiamine is in part mediated through the down-regulation of cyclin A, cyclin B1, cdk2 and p-cdc2 (Tyr15). In order to further elucidate the molecular mechanism underlying evodiamine-induced G2/M phase arrest, we investigated the activation of the DNA damage signaling pathway. DNA damage sensor Chk1/Chk2 plays a role in G2/M checkpoint via the ataxia-telangiectasia mutated (ATM)/ATM-RAD3-related (ATR) pathway. Treatment of evodiamine increased the phosphorylation of Chk1 and Chk2 (Fig. 4) . In addition, the phosphorylation of H2A.X, which is the molecular maker of DNA double-strand breaks, was increased by evodiamine. Based on these observations, it is likely that the anti-proliferative mechanism of evodiamine is related to the induction of G2/M phase cell cycle arrest by inhibiting the levels of cyclin B1 and Cdc-2 (Tyr15) and increase of Chk1 and Chk2 signaling pathway.
Apoptosis is an energy-dependent programmed cell death that is crucial to the balance between cellular survey and death. 16 In the mitochondria-dependent pathway Recently, it has been reported that natural products, such as plumbagin, oridonin and curcumin induced beclin 1-dependent autophagic cell death. [24] [25] [26] Further studies, therefore, are warranted to determine whether evodiamine induces autophagic vacuoles.
The mitogen-activated protein kinase (MAPK) pathways modulate gene expression, differentiation, cell cycle arrest, mitosis, proliferation, motility, metabolism and apoptosis. 27, 28 The MAPK signaling pathways are generally subdivided into three separate pathways: ERK, p38 MAPK and JNK pathways. Many studies have suggested that the MAPK signaling pathway is central to the growth and survival of NSCLC. 29 To determine the specific pathway involved in evodiamine-induced cell death, the effects of evodiamine on MAPK activation were also examined. The findings demonstrate that evodiamine inhibited phosphorylation and expression of ERK, but had no effect on either p38
MAPK or JNK1/2 (data not shown), suggesting that the activation of p38 and JNK1/2 does not play a critical role in evodiamine-induced apoptosis.
In conclusion, the anti-proliferative effects of evodiamine in A549 cells were in part associated with cell cycle arrest at the G2/M phase and induction of apoptosis. These results suggest that evodiamine is an effective natural compound for the treatment of lung cancer.
